Has MVP Bottomed Out With The Change In Market Sentiment?, page-9

It has been suggested by some that their practices are questionable when it comes to what gets approved and what doesn’t.

For example, in the case of the Alzheimer’s Drug Approval for the drug “aducanumab” recently where 3 advisory board members resigned over the FDAs decision to approve it despite their concerns over its efficacy and side effects.

There would be many other examples.
Opioid Crisis in US and growing globally
Penthrox 40+ year safe history of use in Aus for short term pain relief in acute trauma.

Hopefully the new band have the connections and ability to provide what is required to “satisfy” the FDA needs.

IMO DYOR